All In Biotech

Drug Trial Radar · NCT06443489

A Trial of SHR-4849 in Advanced Solid Tumors

A Phase I ,Open-label, Multicenter Clinical Study to Evaluate the Safety, Tolerability , Pharmacokinetics and Efficacy of SHR-4849 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Jun 26, 2024

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Jun 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-4849 injection in Advanced Solid Tumors. To explore the reasonable dosage of SHR-4849 for Advanced Solid Tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SHR-4849Drug

    SHR-4849

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. DLT:the incidence of events associated with the investigational drug determined by the investigator during the observation periodTime frame: up to 21 days
  2. Incidence and severity of AE/SAE:According to NCI-CTCAE v5.0 evaluation criteria, from the signing of informed consent to the end of safety follow-up;Time frame: up to 24 months
  3. MTD or MAD:after all subjects of dose escalation phase be enrolled,and all subjects complete at least one cycle of dosing observation.Time frame: up to 24 months
  4. RP2D:after all subjects of dose escalation and dose expansion phase be enrolled,and all subjects complete at least one cycle of dosing observation.Time frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Jilin Cancer Hospital

    Jilin City, Changchun, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.